메뉴 건너뛰기




Volumn 6, Issue , 2014, Pages 437-449

A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced Non-Small-Cell lung cancer

Author keywords

Heterogeneity; NSCLC; Review; Treatment outcome

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; NAVELBINE; PEMETREXED;

EID: 84908264342     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S63603     Document Type: Review
Times cited : (51)

References (74)
  • 1
    • 84863708472 scopus 로고    scopus 로고
    • Atlanta, GA: American Cancer Society; Accessed July 29, 2012
    • American Cancer Society. Cancer Facts and Figures 2012. Atlanta, GA: American Cancer Society; 2012. Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-031941.pdf. Accessed July 29, 2012.
    • (2012) Cancer Facts and Figures 2012.
    • American Cancer Society1
  • 2
    • 15844380285 scopus 로고    scopus 로고
    • Lung cancer in women: Analysis of the national Surveillance, Epidemiology, and End Results database
    • Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest. 2005;127(3):768-777.
    • (2005) Chest. , vol.127 , Issue.3 , pp. 768-777
    • Fu, J.B.1    Kau, T.Y.2    Severson, R.K.3    Kalemkerian, G.P.4
  • 3
    • 74249107620 scopus 로고    scopus 로고
    • Improving survival for stage IV non-small cell lung cancer: A Surveillance, Epidemiology, and End Results survey from 1990 to 2005
    • Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R. Improving survival for stage IV non-small cell lung cancer: a Surveillance, Epidemiology, and End Results survey from 1990 to 2005. J Thorac Oncol. 2009;4(12):1524-1529.
    • (2009) J Thorac Oncol. , vol.4 , Issue.12 , pp. 1524-1529
    • Morgensztern, D.1    Waqar, S.2    Subramanian, J.3    Gao, F.4    Govindan, R.5
  • 4
    • 79960563357 scopus 로고    scopus 로고
    • A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas
    • Alatorre CI, Carter GC, Chen C, et al. A comprehensive review of predictive and prognostic composite factors implicated in the heterogeneity of treatment response and outcome across disease areas. Int J Clin Pract. 2011;65(8):831-847.
    • (2011) Int J Clin Pract. , vol.65 , Issue.8 , pp. 831-847
    • Alatorre, C.I.1    Carter, G.C.2    Chen, C.3
  • 5
    • 15744374441 scopus 로고    scopus 로고
    • Clinical trial designs for predictive marker validation in cancer treatment trials
    • Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol. 2005;23(9):2020-2027.
    • (2005) J Clin Oncol. , vol.23 , Issue.9 , pp. 2020-2027
    • Sargent, D.J.1    Conley, B.A.2    Allegra, C.3    Collette, L.4
  • 6
    • 0034059515 scopus 로고    scopus 로고
    • Predictive and prognostic factors in small cell lung cancer: Current status
    • Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28(3):173-185.
    • (2000) Lung Cancer. , vol.28 , Issue.3 , pp. 173-185
    • Yip, D.1    Harper, P.G.2
  • 7
    • 74549122386 scopus 로고    scopus 로고
    • Assessing heterogeneity of treatment effects: Are authors misinterpreting their results?
    • Fernandez y Garcia E, Nguyen H, Duan N, Gabler NB, Kravitz RL. Assessing heterogeneity of treatment effects: are authors misinterpreting their results? Health Serv Res. 2010;45(1):283-301.
    • (2010) Health Serv Res. , vol.45 , Issue.1 , pp. 283-301
    • Fernandez y Garcia, E.1    Nguyen, H.2    Duan, N.3    Gabler, N.B.4    Kravitz, R.L.5
  • 8
    • 77955382172 scopus 로고    scopus 로고
    • Assessing and reporting heterogeneity in treatment effects in clinical trials: A proposal
    • Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85.
    • (2010) Trials. , vol.11 , pp. 85
    • Kent, D.M.1    Rothwell, P.M.2    Ioannidis, J.P.3    Altman, D.G.4    Hayward, R.A.5
  • 9
    • 67650763698 scopus 로고    scopus 로고
    • Dealing with heterogeneity of treatment effects: Is the literature up to the challenge?
    • Gabler NB, Duan N, Liao D, Elmore JG, Ganiats TG, Kravitz RL. Dealing with heterogeneity of treatment effects: is the literature up to the challenge? Trials. 2009;10:43.
    • (2009) Trials. , vol.10 , pp. 43
    • Gabler, N.B.1    Duan, N.2    Liao, D.3    Elmore, J.G.4    Ganiats, T.G.5    Kravitz, R.L.6
  • 10
    • 69949162760 scopus 로고    scopus 로고
    • Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
    • Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10): 947-957.
    • (2009) N Engl J Med. , vol.361 , Issue.10 , pp. 947-957
    • Mok, T.S.1    Wu, Y.L.2    Thongprasert, S.3
  • 11
    • 24944442592 scopus 로고    scopus 로고
    • Prognostic factors in advanced cancer patients: Evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care
    • Maltoni M, Caraceni A, Brunelli C, et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005;23(25):6240-6248.
    • (2005) J Clin Oncol. , vol.23 , Issue.25 , pp. 6240-6248
    • Maltoni, M.1    Caraceni, A.2    Brunelli, C.3
  • 12
    • 0036384579 scopus 로고    scopus 로고
    • Prognostic factors in non-small cell lung cancer: A decade of progress
    • Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122(3): 1037-1057.
    • (2002) Chest. , vol.122 , Issue.3 , pp. 1037-1057
    • Brundage, M.D.1    Davies, D.2    McKillop, W.J.3
  • 13
    • 0037250239 scopus 로고    scopus 로고
    • Chemotherapeutic management of stage IV non-small cell lung cancer
    • Socinski MA, Morris DE, Masters GA, Lilenbaum R. Chemotherapeutic management of stage IV non-small cell lung cancer. Chest. 2003;123(Suppl 1):226S-243S.
    • (2003) Chest. , vol.123 , pp. 226S-243S
    • Socinski, M.A.1    Morris, D.E.2    Masters, G.A.3    Lilenbaum, R.4
  • 14
    • 37549005200 scopus 로고    scopus 로고
    • Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials
    • Comella P, Gambardella A, Frasci G, Avallone A, Costanzo R. Comparison of the safety and efficacy of paclitaxel plus gemcitabine combination in young and elderly patients with locally advanced or metastatic non-small cell lung cancer. A retrospective analysis of the Southern Italy Cooperative Oncology Group trials. Crit Rev Oncol Hematol. 2008;65(2):164-171.
    • (2008) Crit Rev Oncol Hematol. , vol.65 , Issue.2 , pp. 164-171
    • Comella, P.1    Gambardella, A.2    Frasci, G.3    Avallone, A.4    Costanzo, R.5
  • 15
    • 76249105307 scopus 로고    scopus 로고
    • Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: A prognostic score from individual data of nine randomized trials
    • Di Maio M, Lama N, Morabito A, et al. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomized trials. Eur J Cancer. 2010;46(4):735-743.
    • (2010) Eur J Cancer. , vol.46 , Issue.4 , pp. 735-743
    • Di Maio, M.1    Lama, N.2    Morabito, A.3
  • 16
    • 84908268613 scopus 로고    scopus 로고
    • Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials [abstract]
    • abstract 6124
    • Di Maio M, Morabito A, Barbera S, et al. Education level as prognostic factor of patients (pts) with advanced non-small cell lung cancer (NSCLC) enrolled in clinical trials [abstract]. J Clin Oncol. 2010;28(Suppl 15):abstract 6124.
    • (2010) J Clin Oncol. , vol.28
    • Di Maio, M.1    Morabito, A.2    Barbera, S.3
  • 17
    • 33748369427 scopus 로고    scopus 로고
    • A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer
    • Hatzidaki D, Agelaki S, Mavroudis D, Vlachonikolis I, Alegakis A, Georgoulias V. A retrospective analysis of second-line chemotherapy or best supportive care in patients with advanced-stage non-small-cell lung cancer. Clin Lung Cancer. 2006;8(1):49-55.
    • (2006) Clin Lung Cancer. , vol.8 , Issue.1 , pp. 49-55
    • Hatzidaki, D.1    Agelaki, S.2    Mavroudis, D.3    Vlachonikolis, I.4    Alegakis, A.5    Georgoulias, V.6
  • 18
    • 15044352688 scopus 로고    scopus 로고
    • Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data
    • Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on Eastern Cooperative Oncology Group data. J Clin Oncol. 2005;23(1):175-183.
    • (2005) J Clin Oncol. , vol.23 , Issue.1 , pp. 175-183
    • Hoang, T.1    Xu, R.2    Schiller, J.H.3    Bonomi, P.4    Johnson, D.H.5
  • 19
    • 0037312404 scopus 로고    scopus 로고
    • Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy
    • Jeremic B, Milicic B, Dagovic A, Aleksandrovic J, Nikolic N. Pretreatment clinical prognostic factors in patients with stage IV non-small cell lung cancer (NSCLC) treated with chemotherapy. J Cancer Res Clin Oncol. 2003;129(2):114-122.
    • (2003) J Cancer Res Clin Oncol. , vol.129 , Issue.2 , pp. 114-122
    • Jeremic, B.1    Milicic, B.2    Dagovic, A.3    Aleksandrovic, J.4    Nikolic, N.5
  • 20
    • 0034488459 scopus 로고    scopus 로고
    • Prognostic factors in advanced non-small cell lung cancer: Elevated serum levels of neuron specific enolase indicate poor prognosis
    • Maeda T, Ueoka H, Tabata M, et al. Prognostic factors in advanced non-small cell lung cancer: elevated serum levels of neuron specific enolase indicate poor prognosis. Jpn J Clin Oncol. 2000;30(12):534-541.
    • (2000) Jpn J Clin Oncol. , vol.30 , Issue.12 , pp. 534-541
    • Maeda, T.1    Ueoka, H.2    Tabata, M.3
  • 21
    • 33747164218 scopus 로고    scopus 로고
    • A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials
    • Mandrekar SJ, Schild SE, Hillman SL, et al. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 2006;107(4): 781-792.
    • (2006) Cancer. , vol.107 , Issue.4 , pp. 781-792
    • Mandrekar, S.J.1    Schild, S.E.2    Hillman, S.L.3
  • 22
    • 43049108821 scopus 로고    scopus 로고
    • Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: The Hellenic Oncology Research Group experience
    • Pallis AG, Polyzos A, Boukovinas I, et al. Pooled analysis of elderly patients with non-small cell lung cancer treated with front line docetaxel/gemcitabine regimen: the Hellenic Oncology Research Group experience. J Thorac Oncol. 2008;3(5):505-510.
    • (2008) J Thorac Oncol. , vol.3 , Issue.5 , pp. 505-510
    • Pallis, A.G.1    Polyzos, A.2    Boukovinas, I.3
  • 23
    • 33646359708 scopus 로고    scopus 로고
    • Changes in the natural history of nonsmall cell lung cancer (NSCLC) - comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990
    • Wakelee HA, Bernardo P, Johnson DH, Schiller JH. Changes in the natural history of nonsmall cell lung cancer (NSCLC) - comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer. 2006;106(10):2208-2217.
    • (2006) Cancer. , vol.106 , Issue.10 , pp. 2208-2217
    • Wakelee, H.A.1    Bernardo, P.2    Johnson, D.H.3    Schiller, J.H.4
  • 24
    • 77957167013 scopus 로고    scopus 로고
    • The influence of sex and histology on outcomes in non-small-cell lung cancer: A pooled analysis of five randomized trials
    • Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol. 2010;21(10):2023-2028.
    • (2010) Ann Oncol. , vol.21 , Issue.10 , pp. 2023-2028
    • Wheatley-Price, P.1    Blackhall, F.2    Lee, S.M.3
  • 25
    • 33750603535 scopus 로고    scopus 로고
    • Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
    • Efficace F, Bottomley A, Smit EF, et al. Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975. Ann Oncol. 2006;17(11):1698-1704.
    • (2006) Ann Oncol. , vol.17 , Issue.11 , pp. 1698-1704
    • Efficace, F.1    Bottomley, A.2    Smit, E.F.3
  • 26
    • 0037842153 scopus 로고    scopus 로고
    • Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592
    • Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003;21(8):1536-1543.
    • (2003) J Clin Oncol. , vol.21 , Issue.8 , pp. 1536-1543
    • Eton, D.T.1    Fairclough, D.L.2    Cella, D.3    Yount, S.E.4    Bonomi, P.5    Johnson, D.H.6
  • 27
    • 27244438585 scopus 로고    scopus 로고
    • Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: A prognostic analysis of the multicenter Italian lung cancer in the elderly study
    • Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005;23(28):6865-6872.
    • (2005) J Clin Oncol. , vol.23 , Issue.28 , pp. 6865-6872
    • Maione, P.1    Perrone, F.2    Gallo, C.3
  • 28
    • 74249111124 scopus 로고    scopus 로고
    • The role of histology with common first-line regimens for advanced non-small cell lung cancer: A brief report of the retrospective analysis of a three-arm randomized trial
    • Scagliotti GV, De Marinis F, Rinaldi M, et al. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol. 2009;4(12):1568-1571.
    • (2009) J Thorac Oncol. , vol.4 , Issue.12 , pp. 1568-1571
    • Scagliotti, G.V.1    De Marinis, F.2    Rinaldi, M.3
  • 29
    • 33644684204 scopus 로고    scopus 로고
    • Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: The Swedish Lung Cancer Study Group
    • Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. J Clin Oncol. 2005;23(33):8380-8388.
    • (2005) J Clin Oncol. , vol.23 , Issue.33 , pp. 8380-8388
    • Sederholm, C.1    Hillerdal, G.2    Lamberg, K.3
  • 30
    • 67649304466 scopus 로고    scopus 로고
    • Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organization LC00-03
    • Teramukai S, Kitano T, Kishida Y, et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organization LC00-03. Eur J Cancer. 2009;45(11):1950-1958.
    • (2009) Eur J Cancer. , vol.45 , Issue.11 , pp. 1950-1958
    • Teramukai, S.1    Kitano, T.2    Kishida, Y.3
  • 31
    • 34247227589 scopus 로고    scopus 로고
    • Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594
    • Wakelee HA, Wang W, Schiller JH, et al. Survival differences by sex for patients with advanced non-small cell lung cancer on Eastern Cooperative Oncology Group trial 1594. J Thorac Oncol. 2006;1(5):441-446.
    • (2006) J Thorac Oncol. , vol.1 , Issue.5 , pp. 441-446
    • Wakelee, H.A.1    Wang, W.2    Schiller, J.H.3
  • 32
    • 33847641797 scopus 로고    scopus 로고
    • The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer
    • Weiss GJ, Rosell R, Fossella F, et al. The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancer. Ann Oncol. 2007;18(3):453-460.
    • (2007) Ann Oncol. , vol.18 , Issue.3 , pp. 453-460
    • Weiss, G.J.1    Rosell, R.2    Fossella, F.3
  • 33
    • 4143145523 scopus 로고    scopus 로고
    • Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients
    • Comella P, Frasci G, Carnicelli P, et al. Gemcitabine with either paclitaxel or vinorelbine vs paclitaxel or gemcitabine alone for elderly or unfit advanced non-small-cell lung cancer patients. Br J Cancer. 2004;91(3):489-497.
    • (2004) Br J Cancer. , vol.91 , Issue.3 , pp. 489-497
    • Comella, P.1    Frasci, G.2    Carnicelli, P.3
  • 34
    • 27144466737 scopus 로고    scopus 로고
    • Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: A multicenter randomized Phase II study
    • Georgoulias V, Agelidou A, Syrigos K, et al. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomized Phase II study. Br J Cancer. 2005;93(7):763-769.
    • (2005) Br J Cancer. , vol.93 , Issue.7 , pp. 763-769
    • Georgoulias, V.1    Agelidou, A.2    Syrigos, K.3
  • 35
    • 32544451788 scopus 로고    scopus 로고
    • Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma
    • Han JY, Lim HS, Lee DH, et al. Randomized Phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer. 2006;106(4): 873-880.
    • (2006) Cancer. , vol.106 , Issue.4 , pp. 873-880
    • Han, J.Y.1    Lim, H.S.2    Lee, D.H.3
  • 36
    • 55049094920 scopus 로고    scopus 로고
    • Treatment outcome in performance status two advanced NSCLC patients administered platinum-based combination chemotherapy
    • Helbekkmo N, Aasebo U, Sundstrom SH, von Plessen C, Brunsvig PF, Bremnes RM. Treatment outcome in performance status two advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer. 2008;62(2):253-260.
    • (2008) Lung Cancer. , vol.62 , Issue.2 , pp. 253-260
    • Helbekkmo, N.1    Aasebo, U.2    Sundstrom, S.H.3    von Plessen, C.4    Brunsvig, P.F.5    Bremnes, R.M.6
  • 37
    • 0036248013 scopus 로고    scopus 로고
    • A Phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: Long-term follow-up results and analysis of prognostic factors
    • Kodani T, Ueoka H, Kiura K, et al. A Phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors. Lung Cancer. 2002;36(3):313-319.
    • (2002) Lung Cancer. , vol.36 , Issue.3 , pp. 313-319
    • Kodani, T.1    Ueoka, H.2    Kiura, K.3
  • 38
    • 0033811566 scopus 로고    scopus 로고
    • 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial
    • Hellenic Cooperative Oncology Group (HeCOG)
    • 2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol. 2000;11(7):799-805.
    • (2000) Ann Oncol. , vol.11 , Issue.7 , pp. 799-805
    • Kosmidis, P.1    Mylonakis, N.2    Skarlos, D.3
  • 39
    • 30744448981 scopus 로고    scopus 로고
    • Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: Impact of comorbidities on safety and efficacy outcome
    • Moscetti L, Nelli F, Padalino D, Sperduti I, Giannarelli D, Pollera CF. Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. J Chemother. 2005;17(6):685-692.
    • (2005) J Chemother. , vol.17 , Issue.6 , pp. 685-692
    • Moscetti, L.1    Nelli, F.2    Padalino, D.3    Sperduti, I.4    Giannarelli, D.5    Pollera, C.F.6
  • 40
    • 77956611568 scopus 로고    scopus 로고
    • Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status
    • Ngeow J, Leong SS, Gao F, et al. Impact of comorbidities on clinical outcomes in non-small cell lung cancer patients who are elderly and/or have poor performance status. Crit Rev Oncol Hematol. 2010;76(1): 53-60.
    • (2010) Crit Rev Oncol Hematol. , vol.76 , Issue.1 , pp. 53-60
    • Ngeow, J.1    Leong, S.S.2    Gao, F.3
  • 41
    • 0035990063 scopus 로고    scopus 로고
    • A three-arm Phase III randomized trial comparing combinations of platinum derivatives, ifosfamide, and/or gemcitabine in stage IV non-small-cell lung cancer
    • Sculier JP, Lafitte JJ, Lecomte J, et al. A three-arm Phase III randomized trial comparing combinations of platinum derivatives, ifosfamide, and/or gemcitabine in stage IV non-small-cell lung cancer. Ann Oncol. 2002;13(6):874-882.
    • (2002) Ann Oncol. , vol.13 , Issue.6 , pp. 874-882
    • Sculier, J.P.1    Lafitte, J.J.2    Lecomte, J.3
  • 42
    • 77952517885 scopus 로고    scopus 로고
    • Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)
    • Bischoff HG, van den Borne B, Pimentel FL, et al. Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study). Curr Med Res Opin. 2010;26(6):1461-1470.
    • (2010) Curr Med Res Opin. , vol.26 , Issue.6 , pp. 1461-1470
    • Bischoff, H.G.1    van den Borne, B.2    Pimentel, F.L.3
  • 43
    • 74249100162 scopus 로고    scopus 로고
    • Third-line chemotherapy in advanced non-small cell lung cancer: Identifying the candidates for routine practice
    • Girard N, Jacoulet P, Gainet M, et al. Third-line chemotherapy in advanced non-small cell lung cancer: identifying the candidates for routine practice. J Thorac Oncol. 2009;4(12):1544-1549.
    • (2009) J Thorac Oncol. , vol.4 , Issue.12 , pp. 1544-1549
    • Girard, N.1    Jacoulet, P.2    Gainet, M.3
  • 44
    • 67049168039 scopus 로고    scopus 로고
    • Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy
    • Koch A, Fohlin H, Sorenson S. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol. 2009;4(3):326-332.
    • (2009) J Thorac Oncol. , vol.4 , Issue.3 , pp. 326-332
    • Koch, A.1    Fohlin, H.2    Sorenson, S.3
  • 45
    • 43049092669 scopus 로고    scopus 로고
    • Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: A Fox Chase Cancer Center retrospective
    • Paralkar VR, Li T, Langer CJ. Population characteristics and prognostic factors in metastatic non-small-cell lung cancer: a Fox Chase Cancer Center retrospective. Clin Lung Cancer. 2008;9(2):116-121.
    • (2008) Clin Lung Cancer. , vol.9 , Issue.2 , pp. 116-121
    • Paralkar, V.R.1    Li, T.2    Langer, C.J.3
  • 46
    • 85029017287 scopus 로고    scopus 로고
    • Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment [abstract]
    • abstract
    • Provencio M, Cobo M, Vazquez-Estevez S, et al. Analysis of prognostic factors in patients with advanced non-small cell lung cancer (NSCLC) who are candidates to receive a second-line treatment [abstract]. J Clin Oncol. 2010;28(suppl 15):abstract e18109.
    • (2010) J Clin Oncol. , vol.28
    • Provencio, M.1    Cobo, M.2    Vazquez-Estevez, S.3
  • 47
    • 77952546399 scopus 로고    scopus 로고
    • Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?
    • Scartozzi M, Mazzanti P, Giampieri R, et al. Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: selecting the unselectable? Lung Cancer. 2010;68(3):433-437.
    • (2010) Lung Cancer. , vol.68 , Issue.3 , pp. 433-437
    • Scartozzi, M.1    Mazzanti, P.2    Giampieri, R.3
  • 48
    • 10444256482 scopus 로고    scopus 로고
    • The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: A retrospective analysis
    • Toh CK, Wong EH, Lim WT, et al. The impact of smoking status on the behavior and survival outcome of patients with advanced non-small cell lung cancer: a retrospective analysis. Chest. 2004;126(6):1750-1756.
    • (2004) Chest. , vol.126 , Issue.6 , pp. 1750-1756
    • Toh, C.K.1    Wong, E.H.2    Lim, W.T.3
  • 49
    • 74549186434 scopus 로고    scopus 로고
    • Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer
    • Wang XS, Shi Q, Lu C, et al. Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010;116(1):137-145.
    • (2010) Cancer. , vol.116 , Issue.1 , pp. 137-145
    • Wang, X.S.1    Shi, Q.2    Lu, C.3
  • 50
  • 51
    • 70350558459 scopus 로고    scopus 로고
    • Patient attitudes towards chemotherapy and survival: A prospective observational study in advanced non-small cell lung cancer
    • Chu DT, Kim SW, Hsu HK, et al. Patient attitudes towards chemotherapy and survival: a prospective observational study in advanced non-small cell lung cancer. Lung Cancer. 2009;66(2):250-256.
    • (2009) Lung Cancer. , vol.66 , Issue.2 , pp. 250-256
    • Chu, D.T.1    Kim, S.W.2    Hsu, H.K.3
  • 52
    • 33845673604 scopus 로고    scopus 로고
    • Influence of histological type, smoking history, and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer
    • Itaya T, Yamaoto N, Ando M, et al. Influence of histological type, smoking history, and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci. 2007;98(2):226-230.
    • (2007) Cancer Sci. , vol.98 , Issue.2 , pp. 226-230
    • Itaya, T.1    Yamaoto, N.2    Ando, M.3
  • 53
    • 48749114956 scopus 로고    scopus 로고
    • Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients
    • Jacot W, Colinet B, Bertrand D, et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol. 2008;19(8):1458-1464.
    • (2008) Ann Oncol. , vol.19 , Issue.8 , pp. 1458-1464
    • Jacot, W.1    Colinet, B.2    Bertrand, D.3
  • 54
    • 0033737428 scopus 로고    scopus 로고
    • The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer
    • Shepherd FA, Abratt R, Crino L, et al. The influence of gemcitabine and cisplatin schedule on response and survival in advanced non-small cell lung cancer. Lung Cancer. 2000;30(2):117-125.
    • (2000) Lung Cancer. , vol.30 , Issue.2 , pp. 117-125
    • Shepherd, F.A.1    Abratt, R.2    Crino, L.3
  • 55
    • 34249789939 scopus 로고    scopus 로고
    • A Phase III randomized trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer
    • Sculier JP, Lafitte JJ, Lecomte J, et al. A Phase III randomized trial comparing sequential chemotherapy using cisplatin-based regimen and paclitaxel to cisplatin-based chemotherapy alone in advanced non-small-cell lung cancer. Ann Oncol. 2007;18(6):1037-1042.
    • (2007) Ann Oncol. , vol.18 , Issue.6 , pp. 1037-1042
    • Sculier, J.P.1    Lafitte, J.J.2    Lecomte, J.3
  • 56
    • 85029017106 scopus 로고    scopus 로고
    • Impact of histology and smoking status on survival outcome of patients with advanced non-small cell lung cancer (NSCLC): West Japan Oncology Group (WJOG) study 3906L [abstract]
    • abstract
    • Kogure Y, Ando M, Chiba Y, et al. Impact of histology and smoking status on survival outcome of patients with advanced non-small cell lung cancer (NSCLC): West Japan Oncology Group (WJOG) study 3906L [abstract]. J Clin Oncol. 2010;28(Suppl 15):abstract e18013.
    • (2010) J Clin Oncol. , vol.28
    • Kogure, Y.1    Ando, M.2    Chiba, Y.3
  • 57
    • 69549086346 scopus 로고    scopus 로고
    • Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer
    • Qi Y, Schild SE, Mandrekar SJ, et al. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol. 2009;4(9): 1075-1082.
    • (2009) J Thorac Oncol. , vol.4 , Issue.9 , pp. 1075-1082
    • Qi, Y.1    Schild, S.E.2    Mandrekar, S.J.3
  • 58
    • 34249813419 scopus 로고    scopus 로고
    • Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: A study by the European Lung Cancer Working Party
    • Berghmans T, Lafitte JJ, Lecomte J, et al. Second-line paclitaxel in non-small cell lung cancer initially treated with cisplatin: a study by the European Lung Cancer Working Party. Br J Cancer. 2007;96(11): 1644-1649.
    • (2007) Br J Cancer. , vol.96 , Issue.11 , pp. 1644-1649
    • Berghmans, T.1    Lafitte, J.J.2    Lecomte, J.3
  • 59
    • 85042898859 scopus 로고    scopus 로고
    • The mid-arm muscle circumference measurement and the prognosis of stage IV non-small cell lung cancer patients [abstract]
    • abstract
    • Tartari RF, Abreu Nunes C, Moreira J, et al. The mid-arm muscle circumference measurement and the prognosis of stage IV non-small cell lung cancer patients [abstract]. J Clin Oncol. 2010;28(Suppl 15):abstract e18058.
    • (2010) J Clin Oncol. , vol.28
    • Tartari, R.F.1    Abreu Nunes, C.2    Moreira, J.3
  • 60
    • 68549094542 scopus 로고    scopus 로고
    • Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of two: Prognostic factors and treatment selection based on two large randomized clinical trials
    • Lilenbaum R, Villaflor VM, Langer C, et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of two: prognostic factors and treatment selection based on two large randomized clinical trials. J Thorac Oncol. 2009;4(7):869-874.
    • (2009) J Thorac Oncol. , vol.4 , Issue.7 , pp. 869-874
    • Lilenbaum, R.1    Villaflor, V.M.2    Langer, C.3
  • 61
    • 62849115084 scopus 로고    scopus 로고
    • Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy
    • Li J, Chen P, Dai CH, Li XQ, Bao QL. Prognostic factors in elderly patients with advanced non-small cell lung cancer treated with chemotherapy. Oncology. 2009;76(5):355-362.
    • (2009) Oncology. , vol.76 , Issue.5 , pp. 355-362
    • Li, J.1    Chen, P.2    Dai, C.H.3    Li, X.Q.4    Bao, Q.L.5
  • 62
    • 41749085781 scopus 로고    scopus 로고
    • Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients
    • Goto Y, Sekine I, Yamada K, et al. Influence of previous chemotherapy on the efficacy of subsequent docetaxel therapy in advanced non-small cell lung cancer patients. J Thorac Oncol. 2008;3(4):412-416.
    • (2008) J Thorac Oncol. , vol.3 , Issue.4 , pp. 412-416
    • Goto, Y.1    Sekine, I.2    Yamada, K.3
  • 63
    • 34347379142 scopus 로고    scopus 로고
    • Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
    • Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847-857.
    • (2007) J Natl Cancer Inst. , vol.99 , Issue.11 , pp. 847-857
    • Ardizzoni, A.1    Boni, L.2    Tiseo, M.3
  • 64
    • 77954426249 scopus 로고    scopus 로고
    • A comparison of white and African American outcomes from a three-arm, randomized, Phase III multicenter trial of advanced or metastatic non-small cell lung cancer
    • Obasaju CK, Ansari RH, Socinski MA, et al. A comparison of white and African American outcomes from a three-arm, randomized, Phase III multicenter trial of advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 2010;5(7):993-1000.
    • (2010) J Thorac Oncol. , vol.5 , Issue.7 , pp. 993-1000
    • Obasaju, C.K.1    Ansari, R.H.2    Socinski, M.A.3
  • 65
    • 0035698002 scopus 로고    scopus 로고
    • Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy?
    • Soria JC, Brisgand D, Le Chevalier T. Do all patients with advanced non-small-cell lung cancer benefit from cisplatin-based combination therapy? Ann Oncol. 2001;12(12):1667-1670.
    • (2001) Ann Oncol. , vol.12 , Issue.12 , pp. 1667-1670
    • Soria, J.C.1    Brisgand, D.2    Le Chevalier, T.3
  • 66
    • 77949624488 scopus 로고    scopus 로고
    • Prognostic and predictive factors in a randomized Phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
    • Syrigos KN, Vansteenkiste J, Parikh P, et al. Prognostic and predictive factors in a randomized Phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. Ann Oncol. 2010;21(3):556-561.
    • (2010) Ann Oncol. , vol.21 , Issue.3 , pp. 556-561
    • Syrigos, K.N.1    Vansteenkiste, J.2    Parikh, P.3
  • 67
    • 61449455071 scopus 로고    scopus 로고
    • The prognostic and predictive role of histology in advanced non-small cell lung cancer: A literature review
    • Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M. The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol. 2008;3(12): 1468-1481.
    • (2008) J Thorac Oncol. , vol.3 , Issue.12 , pp. 1468-1481
    • Hirsch, F.R.1    Spreafico, A.2    Novello, S.3    Wood, M.D.4    Simms, L.5    Papotti, M.6
  • 68
    • 30644460000 scopus 로고    scopus 로고
    • Non small cell lung cancer patients with ECOG PS2: Unsolved questions and lessons from clinical trials
    • Gebbia V, Galetta D, De Marinis F. Non small cell lung cancer patients with ECOG PS2: unsolved questions and lessons from clinical trials. Ann Oncol. 2005;16(Suppl 4):iv123-iv131.
    • (2005) Ann Oncol. , vol.16 , pp. iv123-iv131
    • Gebbia, V.1    Galetta, D.2    De Marinis, F.3
  • 69
    • 79960209587 scopus 로고    scopus 로고
    • Prognostic factors in stage III non-small cell lung cancer: A review of conventional, metabolic, and new biological variables
    • Berghmans T, Paesmans M, Sculier JP. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic, and new biological variables. Ther Adv Med Oncol. 2011;3(3):127-138.
    • (2011) Ther Adv Med Oncol. , vol.3 , Issue.3 , pp. 127-138
    • Berghmans, T.1    Paesmans, M.2    Sculier, J.P.3
  • 72
    • 78651066494 scopus 로고    scopus 로고
    • Treatment-by-histology interaction analyses in three Phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer
    • Scagliotti G, Brodowicz T, Shepherd F, et al. Treatment-by-histology interaction analyses in three Phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol. 2011;6(1):64-70.
    • (2011) J Thorac Oncol. , vol.6 , Issue.1 , pp. 64-70
    • Scagliotti, G.1    Brodowicz, T.2    Shepherd, F.3
  • 73
    • 77956266591 scopus 로고    scopus 로고
    • Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer
    • Sandler A, Yi J, Dahlberg S, et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010;5(9):1416-1423.
    • (2010) J Thorac Oncol. , vol.5 , Issue.9 , pp. 1416-1423
    • Sandler, A.1    Yi, J.2    Dahlberg, S.3
  • 74
    • 0033653516 scopus 로고    scopus 로고
    • Behavior of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: Relationship with response to therapy and survival
    • Orditura M, Romano C, De Vita F, et al. Behavior of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival. Cancer Immunol Immunother. 2000;49(10):530-536.
    • (2000) Cancer Immunol Immunother. , vol.49 , Issue.10 , pp. 530-536
    • Orditura, M.1    Romano, C.2    De Vita, F.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.